Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Big bank profits surged in the fourth quarter and Wall Street roared back to life, with net income rising 50% at JPMorgan Chase and more than doubling at Goldman Sachs. Hindenburg Research founder ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

The move comes more than 30 years since the Food and Drug Administration prohibited the use of Red No. 3 in cosmetics after ...

The US Food and Drug Administration is proposing limits on the level of nicotine in cigarettes and some other types of ...